Department of Diabetes and Endocrinology, University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, UK; School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
Department of Diabetes and Endocrinology, University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, UK.
Diabetes Res Clin Pract. 2024 Mar;209:111597. doi: 10.1016/j.diabres.2024.111597. Epub 2024 Feb 27.
To evaluate real-world outcomes in people with Type 1 Diabetes (PwT1D) initiated on Omnipod DASH® Insulin Management System.
Anonymized clinical data were submitted to a secure web-based tool within the National Health Service network. Hemoglobin A1c (HbA1c), sensor-derived glucometrics, total daily dose of insulin (TDD), and patient-reported outcome changes between baseline and follow-up were assessed. Individuals were classified to "new-to-pump" (switched from multiple daily injections) and "established-on-pump" (switched from a tethered insulin pump) groups.
276 individuals from 11 centers [66.7 % female; 92 % White British; median age 41 years (IQR 20-50); diabetes duration 20 years (IQR 11-31); 49.3 % within "new-to-pump" group] were included. Baseline HbA1c was 8.0 ± 1.3 % (64 ± 14 mmol/mol). At follow-up [3 years (IQR 1.5-3.2)], HbA1c reduced by 0.3 % [(3 mmol/mol); p = 0.002] across the total population, 0.4 % [(5 mmol/mol); p = 0.001] in those "new-to-pump" and remained unchanged in those "established-on-pump". TDD decreased in the "new-to-pump" cohort (baseline:44.9 ± 21.0units vs follow-up:38.1 ± 15.4units, p = 0.002). Of those asked, 141/143 (98.6 %) stated Omnipod DASH had a positive impact on quality of life.
Omnipod DASH was associated with improvements in HbA1c in PwT1D "new-to-pump" and maintained previous HbA1c levels in those "established-on-pump". User satisfaction in all groups and TDD reduction in those "new-to-pump" were reported.
评估接受 Omnipod DASH®胰岛素管理系统治疗的 1 型糖尿病患者（PwT1D）的真实世界结局。
匿名临床数据被提交到英国国民保健署网络中的一个安全的网络工具。评估糖化血红蛋白（HbA1c）、传感器衍生的血糖指标、胰岛素总日剂量（TDD）以及患者报告的结局变化，这些都是基于基线和随访数据得出的。患者被分为“新用泵”（从多次皮下注射转为用泵）和“已用泵”（从有绳胰岛素泵转为用泵）两组。
共纳入来自 11 个中心的 276 名患者（66.7%为女性；92%为白种英国人；中位年龄 41 岁（IQR 20-50）；糖尿病病程 20 年（IQR 11-31）；49.3%为“新用泵”组）。基线时的 HbA1c 为 8.0±1.3%（64±14mmol/mol）。在随访期间[3 年（IQR 1.5-3.2）]，HbA1c 整体降低了 0.3%（3mmol/mol；p=0.002），“新用泵”组降低了 0.4%（5mmol/mol；p=0.001），而“已用泵”组则无变化。“新用泵”组的 TDD 降低（基线：44.9±21.0 单位 vs 随访：38.1±15.4 单位，p=0.002）。在被问到的 143 名患者中，有 141 名（98.6%）表示 Omnipod DASH 对生活质量有积极影响。
Omnipod DASH 与“新用泵”组的 PwT1D 患者的 HbA1c 改善相关，并且保持了“已用泵”组的 HbA1c 水平。所有组的患者满意度以及“新用泵”组 TDD 的降低都有报道。
